Jury verdict favours AstraZeneca in Nexium antitrust litigation

AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.

AstraZeneca is pleased with the jury’s verdict. The Company has always maintained that the plaintiffs’ allegations were without merit.

All parties have appellate rights.

Two cases making similar allegations were filed by numerous purchasers in the state court in Pennsylvania and are still pending.

– ENDS –

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler  +44 20 7604 8030 (UK/Global)

Vanessa Rhodes  +44 20 7604 8037 (UK/Global)

Ayesha Bharmal  +44 20 7604 8034 (UK/Global)

Jacob Lund  +46 8 553 260 20 (Sweden)

Michele Meixell  + 1 302 885 6351 (US)

Investor Enquiries

Thomas Kudsk Larsen  +44 20 7604 8199 mob: +44 7818 524185  

Karl Hård  +44 20 7604 8123 mob: +44 7789 654364

Eugenia Litz  +44 20 7604 8233 mob: +44 7884 735627

Christer Gruvris    +44 20 7604 8126   mob: +44 7827 836825